Spark Biomedical

Spark Biomedical is a private, commercial-stage medical device company developing wearable neurostimulation devices as drug-free alternatives for complex conditions. Its flagship product, the Sparrow Ascent system, is FDA-cleared for aiding opioid withdrawal relief and serves as the core platform for future indications. Founded in 2017 and based in Dallas, Texas, the company targets significant unmet needs in addiction medicine, mental health, and other therapeutic areas by modulating the autonomic nervous system through a non-invasive auricular device.

Transcutaneous Auricular Neurostimulation (tAN®) - a non-invasive, wearable bioelectronic medicine platform that delivers targeted neurostimulation through the ear to modulate the autonomic nervous system.

Spark Biomedical competes in the non-invasive neuromodulation space, facing rivals like electroCore (gammaCore for headache) and other tVNS (transcutaneous Vagus Nerve Stimulation) devices. In opioid withdrawal, it competes against established pharmacological therapies (MAT) and other detox aids. Its broad platform strategy pits it against more specialized device companies across multiple therapeutic areas.